Drug Profile
Research programme: tankyrase inhibitors - Novartis
Alternative Names: XAV-939Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Novartis Institutes for BioMedical Research
- Class Small molecules
- Mechanism of Action Tankyrase inhibitors; Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer